Avanos Medical Stock Price, News & Analysis

WRS Group announced it will acquire substantially all assets and rights to Avanos Medical (NYSE: AVNS) US Game Ready® orthopedic rental business, with ownership transfer effective Dec. 1, 2025.

The transaction includes a long-term distribution and supply agreement: Avanos will continue to manufacture and supply Game Ready systems and accessories and provide transition support through the end of 2025 to ensure uninterrupted customer service.

WRS said the acquisition strengthens its US orthopedic recovery offerings and aims to expand access to clinically proven cold-and-compression therapies for patients, surgeons, and rehabilitation providers.

Avanos Medical (NYSE: AVNS) has announced the acquisition of Nexus Medical, a private medical device company known for its proprietary TKO® anti-reflux needleless connector technology. The technology is specifically designed for safer nutrition and medication delivery in high-acuity settings like NICUs and PICUs.

The strategic acquisition enhances Avanos' Specialty Nutrition Systems business, particularly strengthening its position in neonatal patient care. The TKO® technology features a patented pressure-activated tri-seal silicone valve that reduces blood reflux issues during IV-based treatments.

The transaction was financed with available cash and is expected to be immediately accretive to revenue growth and earnings per share.

Avanos Medical (NYSE:AVNS) has announced two significant leadership changes. Scott Galovan has been appointed as Senior Vice President and Chief Financial Officer, effective August 1, 2025. Galovan, who previously served as SVP of strategy and corporate development at Avanos, brings 12 years of company experience and a strong background in acquisitions and divestitures.

Additionally, CEO David Pacitti has been appointed to the company's Board of Directors, also effective August 1, 2025. In his CFO role, Galovan will oversee global finance, treasury, tax, corporate development, investor relations, accounting, and the Enterprise Program Management Office, reporting directly to Pacitti.

Avanos Medical (NYSE:AVNS) reported Q2 2025 financial results with total net sales of $175.0 million, up 1.9% year-over-year. The company posted a net loss of $76.8 million, compared to net income of $4.3 million in Q2 2024, primarily due to a $77.0 million goodwill impairment charge.

The Specialty Nutrition Systems segment showed strong performance with net sales of $102.7 million, while Pain Management & Recovery segment reached $61.0 million. The company announced the divestiture of its HA product line to Channel-Markers Medical and maintained its 2025 guidance of revenue between $665-685 million and adjusted EPS of $0.75-0.95.

Avanos Medical (NYSE:AVNS) has announced the divestiture of its Hyaluronic Acid (HA) product line to Channel-Markers Medical (CMM), a private company in Raleigh, NC. The divested portfolio includes TriVisc® and GenVisc® 850 injection products for osteoarthritis knee pain treatment.

The strategic move aligns with Avanos' transformation strategy to focus on its core segments in Pain Management & Recovery and Specialty Nutrition Systems. The ownership transfer is effective immediately, with Avanos providing transition support through the end of 2025 to ensure continuity of service.

Avanos Medical (NYSE: AVNS) has scheduled a conference call to discuss its second quarter 2025 financial results on Tuesday, August 5, at 9 a.m. ET. The company will release its financial results before the market opens on the same day.

The call will be led by CEO Dave Pacitti, interim CFO Jason Pickett, and SVP of Strategy Scott Galovan. Investors can join via phone using an automatic registration link or dial in manually. A simultaneous webcast and presentation will be available through the company's investor relations website, with replay access available for one week after the call.

Avanos Medical (NYSE: AVNS) has appointed Camille Chang Gilmore as Senior Vice President and Chief Human Resources Officer. Gilmore, who previously served as Boston Scientific's global chief diversity officer and VP of HR for Interventional Cardiology, brings over 25 years of experience in building high-performing organizations. In her new role, she will oversee Avanos' people strategy, including talent acquisition, workforce planning, leadership development, and employee experience. Her extensive background includes HR leadership positions at companies like Boston Scientific, Guidant, IBM, and academic institutions. Gilmore holds a bachelor's degree in business management from Penn State and an MBA from the University of Illinois at Urbana-Champaign.

Avanos Medical (NYSE: AVNS) reported Q1 2025 financial results with total net sales of $167.5 million, up 0.8% year-over-year. The company's net income increased to $6.6 million ($0.14 per share) compared to $0.5 million ($0.01 per share) in Q1 2024. Adjusted diluted EPS rose to $0.26 from $0.22. Key segment performance: - Specialty Nutrition Systems: $101.1M in sales with 8.7% volume growth - Pain Management & Recovery: $56.2M in sales with mixed results The company maintained its 2025 revenue guidance of $665-685M but lowered adjusted EPS guidance to $0.75-0.95 due to tariff impacts. Cash position stood at $97.0M, with total debt of $107.4M as of March 31, 2025.

Avanos Medical (NYSE: AVNS) has scheduled a conference call to discuss its first quarter 2025 financial results on Tuesday, May 6 at 9 a.m. ET. The company will release its detailed results before the market opens on the same day.

The conference call will feature key leadership including CEO Dave Pacitti, interim CFO Jason Pickett, SVP of Strategy and Corporate Development Scott Galovan, and Board Chairman Gary Blackford. Participants can join via phone through an automatic registration system or through manual dialing options.

A simultaneous webcast and presentation will be available through the Investors section of Avanos Medical's website. The replay will be accessible for one week following the call.